Evidence map›Paper›PMID 38895772›Full record

ArticleClinical cardiology2024

The Effect of Different Statin-Based Lipid-Lowering Strategies on C-Reactive Protein Levels in Patients With Stable Coronary Artery Disease.

Zhimin Xue, Miao Ye, Hangpan Jiang, Duanbin Li, Xulin Hong, Zhezhe Chen, Ya Li, Binquan Zhou, Wenbin Zhang, Miaoyun Wang

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. The role of IL-6 in atherosclerosis: a narrative review.Frontiers in cardiovascular medicine · 2026
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zhimin XueDepartment of Cardiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Zhejiang, Hangzhou, China.
Miao YeDepartment of Cardiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Zhejiang, Hangzhou, China.
Hangpan JiangDepartment of Cardiology, The Fourth Affiliated Hospital, College of Medicine, Zhejiang University, Zhejiang, China.
Duanbin LiDepartment of Cardiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Zhejiang, Hangzhou, China.
Xulin HongDepartment of Cardiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Zhejiang, Hangzhou, China.ORCID http://orcid.org/0000-0003-2417-4796
Zhezhe ChenDepartment of Cardiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Zhejiang, Hangzhou, China.
Ya LiDepartment of Cardiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Zhejiang, Hangzhou, China.ORCID http://orcid.org/0000-0002-3216-5403
Binquan ZhouDepartment of Cardiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Zhejiang, Hangzhou, China.
Wenbin ZhangDepartment of Cardiology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Zhejiang, Hangzhou, China.ORCID http://orcid.org/0000-0003-4746-9570
Miaoyun WangHangzhou Medical College Affiliated Lin An People's Hospital, Hangzhou, China.

Funding

Medical Health Science and Technology Project of Zhejiang Provincial Health Commission 2020KY596Medical Health Science and Technology Project of Zhejiang Provincial Health Commission 2021RC014National Natural Science Foundation of China 82070408Traditional Chinese Medicine Science and Technology Project of Zhejiang Province 2021ZB172
6 · The paper itself

Abstract

backgroundStatins are lipid-lowering drugs with favorable anti-inflammatory effects. This study aimed to explore different statin-based lipid-lowering strategies to reduce high-sensitivity C-reactive protein (hs-CRP). HYPOTHESIS: The hypothesis is that different statin-based lipid-lowering strategies might reduce hs-CRP.

methodsThis retrospective study included 3653 patients who underwent percutaneous coronary intervention (PCI). Three statin-based lipid-lowering strategies were investigated, including different types of statins (atorvastatin vs. rosuvastatin), statin combined with ezetimibe therapy (vs. without), and intensive statin therapy (vs. regular). The hs-CRP levels and blood lipid indicators were measured at baseline and after 1-month lipid-lowering therapy. Multivariable linear regression analysis and structural equation mode analysis were conducted to verify the association between different lipid-lowering strategies, Δhs-CRP (%) and ΔLDL-C (%).

resultsTotally, 3653 patients were enrolled with an average age of 63.81 years. Multivariable linear regression demonstrated that statin combined with ezetimibe therapy was significantly associated with decreased Δhs-CRP (%) (β = -0.253, 95% CI: [-0.501 to -0.005], p = 0.045). The increased ΔLDL-C (%) was an independent predictor of elevated levels of Δhs-CRP (%) (β = 0.487, 95% CI: [0.15-0.824], p = 0.005). Furthermore, structural equation model analysis proved that statin combined with ezetimibe therapy (β = -0.300, p < 0.001) and intensive statin therapy (β = -0.032, p = 0.043) had an indirect negative effect on Δhs-CRP via ΔLDL-C.

conclusionsCompared with routine statin use, statin combined with ezetimibe therapy and intensive statin therapy could further reduce hs-CRP levels.

Indexed as

BiomarkersCoronary Artery DiseaseC-Reactive ProteinEzetimibeHydroxymethylglutaryl-CoA Reductase InhibitorsPercutaneous Coronary InterventionAgedAnticholesteremic AgentsAtorvastatinCholesterol, LDLDrug Therapy, CombinationDyslipidemiasFemaleHumansMaleMiddle AgedAnticholesteremic AgentsAtorvastatinBiomarkersCholesterol, LDLC-Reactive ProteinEzetimibeHydroxymethylglutaryl-CoA Reductase InhibitorsRosuvastatin Calciumezetimibeinflammationlipid‐lowering therapystable coronary artery diseasestatin

Identifiers

PMID38895772
PMCPMC11187842

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.